Anti-SARS-CoV-2 Monoclonal Antibodies for Long COVID (COVID-19)
Anti-SARS-CoV-2 Monoclonal Antibodies for Long COVID (COVID-19)
Active, not recruiting · NCT05877508 · Registry updated 2025-10-28Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Anti-SARS-CoV-2 Monoclonal Antibodies for Long COVID (COVID-19) | COVID-19, Chronic Disease, Coronaviridae Infections, Disease Attributes, Infections, Nidovirales infectious disease, Orthocoronavirinae infectious disease, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Post-Infectious Disorders, RNA Virus Infections, long COVID-19, lung disorder, pneumonia, respiratory system disorder, respiratory tract infectious disorder, viral infectious disease, viral pneumonia | Active, not recruiting | Phase 2 | 2025-10-28 | NCT05877508 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Aerium Therapeutics | 1 |
| Michael Peluso, MD | 2 |
| Patient-Led Research Collaborative | 1 |
| PolyBio Research Foundation | 5 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| UCSF/Zuckerberg San Francisco General Hospital | San Francisco | United States | 2 |